More tools:Markets·Screener·Research·Chat

Genprex, Inc. Common Stock (GNPX) Financial Statements

Genprex, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00F7T0166
XNAS · usd
3.54▲ 0.04 (1.14%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close3.50
Day's Range3.42 – 3.65
52-Week Range0.16 – 12.97
Volume28.3K
Avg Volume296.1K
Share Statistics
Shares Outstanding
Employees13
ExchangeXNAS
Listed2018-03-29
Share count as of August 10, 2026
Loading Income Statement…
Key questions about Genprex, Inc. Common Stock (GNPX)
What is Genprex, Inc. Common Stock's Market Cap?
Genprex, Inc. Common Stock's Market Cap is $2.9M, based on as-reported figures from SEC (XBRL) filings.
What is Genprex, Inc. Common Stock's Enterprise Value?
Genprex, Inc. Common Stock's Enterprise Value is -$12.3M, based on as-reported figures from SEC (XBRL) filings.
What is Genprex, Inc. Common Stock's EV / EBITDA?
Genprex, Inc. Common Stock's EV / EBITDA is 0.8×, based on as-reported figures from SEC (XBRL) filings.
What is Genprex, Inc. Common Stock's Net Income (TTM)?
Genprex, Inc. Common Stock's Net Income (TTM) is -$16.5M, based on as-reported figures from SEC (XBRL) filings.
What is Genprex, Inc. Common Stock's EBITDA?
Genprex, Inc. Common Stock's EBITDA is -$15.8M, based on as-reported figures from SEC (XBRL) filings.
What is Genprex, Inc. Common Stock's Diluted EPS (TTM)?
Genprex, Inc. Common Stock's Diluted EPS (TTM) is -20.13, based on as-reported figures from SEC (XBRL) filings.
What is Genprex, Inc. Common Stock's Net Debt?
Genprex, Inc. Common Stock's Net Debt is -$15.2M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development—
General and administrative—
Total operating expenses—
Operating loss—
Other income—
Realized and unrealized (loss) gain———
Net loss
Net loss per share applicable to common stockholders — basic and diluted (in dollars per share)——